CureVac (NASDAQ:CVAC) is working on mRNA coronavirus vaccine candidates. If it's successful, mRNA vaccine giants Moderna and Pfizer will face competition. In this Motley Fool Live video recorded on June 22, healthcare and cannabis bureau editor and analyst Olivia Zitkus and contributor Adria Cimino discuss whether investors should buy CureVac shares as a way to invest in this game-changing technology.

Olivia Zitkus: How do you feel about it as an mRNA bet? People talk about Moderna as a bet on mRNA for the rest of their pipeline. What do you think about CureVac? Like you've mentioned, once they have the technology in place, it's a lot easier to set up a new vaccine to change the code -- I'll use that language -- and instruct the body to produce something slightly different for maybe a different variant of the coronavirus or a different virus or disease altogether. What do you think about this mRNA bet, purely?

Adria Cimino: Well, I think right now it's still risky because Moderna has shown, "Hey, we can do this." So now let's apply it to lots of different areas. CureVac, because of this data, they're going to have to show us that they can do it. They're going to have to show better data I think before we can say, OK. Right now, it's maybe a bet for very aggressive investors because they figure, well, hey, I can get it at a very good price, and I will make a small position in this whereas Moderna has gone up quite a bit. But I would feel a little bit... definitely more confident investing right now in Moderna, because they've proven that they can do this, and they've got the data behind it and everything. Right now, CureVac is still pretty risky.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis -- even one of our own -- helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.